Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide in Cisplatin-Refractory Germ Cell Tumors
NCT00006043Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2000
- Primary completion
- Nov 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in germ cell tumor (GCT), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Efficacy. Started Feb 2000; status: completed.
02
Drugs
temozolomide
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT00006043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006043.